News
-
-
COMMUNIQUÉ DE PRESSE
Sensirion Holding AG: Sensirion ends activities in condition monitoring; focusing on methane emission monitoring as a data-based service business
Sensirion Holding AG ends activities in condition monitoring to focus on methane emission monitoring as a data-based service business, aiming for improved operating cash flow from 2025 -
-
COMMUNIQUÉ DE PRESSE
Avant Brands Issues Correction to Recently Announced Private Placement
Avant Brands Inc. issues correction for non-brokered private placement to raise gross proceeds of up to $3,888,888, with each unit including one Common Share and one-half of a Warrant. Offering expected to close on April 30, 2024, subject to TSX approval -
-
COMMUNIQUÉ DE PRESSE
Board-Certified and Highly Accomplished Active Duty Military Ophthalmologist Now Treating Patients at LasikPlus Lexington
Kentucky-based ophthalmologist Dr. Gregory Bryant Giles, renowned for laser refractive surgery, now treats patients at LasikPlus Lexington. Known for exceptional skills in LASIK, PRK, and cataract surgery, Dr. Giles has years of experience and significant contributions in ophthalmology -
COMMUNIQUÉ DE PRESSE
Inspire Veterinary Partners Reports Full Year 2023 Financial Results
Inspire Veterinary Partners, Inc. reports approximately 70% revenue growth year-over-year to $16.7M in 2023. Cost reduction initiatives and SG&A savings drive operational efficiency and profitability. Expansion in pet health sector remains promising -
-
COMMUNIQUÉ DE PRESSE
Ur-Energy Announces Appointment of New Board Members: John Paul Pressey and Elmer W. Dyke
Ur-Energy Inc. appoints John Paul Pressey and Elmer W. Dyke as new Board members, announces retirement of James M. Franklin and W. William Boberg. Company expresses gratitude towards retiring Directors -
COMMUNIQUÉ DE PRESSE
Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
Data4Cure announces the release of the Single-Cell Immune Checkpoint Inhibition Atlas at AACR 2024, facilitating insights on cancer immunotherapy. CEO highlights integration of high-throughput data for new therapies
